ArticlePloS one2024
Characterization of human exposure to Anopheles and Aedes bites using antibody-based biomarkers in rural zone of Cameroon.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria and Aedes-borne diseases remain major causes of mortality, morbidity, and disability in most developing countries. Surveillance of transmission patterns associated with vector control remains strategic for combating these diseases. Due to the limitions of current surveillance tools used to assess human exposure to mosquito bites, human antibody (Ab) responses to salivary peptides from Anopheles (gSG6-P1) and Aedes (Nterm-34kDa) are increasingly being used to measure direct human-Anopheles or Aedes contact. This study reports on the assessment of Human IgG Ab responses to gSG6-P1 and Nterm-34-kDa salivary peptides as biomarkers to track exposure to Anopheles and Aedes bites, in rural localities of Cameroon. Blood samples were collected between October and November 2022 from 173 individuals residing in four villages: Njombe, Kekem, Belabo, and Ouami. Sociodemographic characteristics and information regarding Long Lasting Insecticide Net (LLIN) ownership, use, and net characteristics were recorded using a questionnaire. The measurement of human IgG levels to gSG6-P1 and Nterm-34kDa peptides was conducted in blood samples using ELISA. The levels of IgG responses to Anopheles gSG6-P1 and Aedes Nterm-34kDa salivary peptides varied significantly across villages (all p<0.05). IgG responses to Anopheles gSG6-P1 were higher in Njombe compared to Belabo and Ouami (all p<0.01), while IgG responses to Aedes Nterm-34kDa were higher in Kekem compared to the other villages (all p<0.0001). Aweak correlation was observed between IgG responses to Anopheles and Aedes salivary peptides (Spearman r = 0.2689, p = 0.0003). However, the median level of IgG to Anopheles gSG6-P1 was higher than IgG to Aedes Nterm-34kDa in Njombé, Belabo, and Ouami. Individuals not using their LLIN, those using damaged bed nets, and those who reported vegetation around their houses developed higher IgG responses to gSG6-P1 and Nterm-34 kDa compared to those who did not (all p<0.05). The immune-epidemiological biomarkers have shown promising potential as indicators for monitoring human exposure to various mosquito bites and their heterogeneity in the same site. However, additional research is needed to validate the efficacy of this technique for surveillance purposes and to assess the effectiveness of vector control interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.